Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Sees Large Drop in Short Interest

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the target of a large drop in short interest in June. As of June 15th, there was short interest totaling 48,137 shares, a drop of 83.9% from the May 31st total of 298,780 shares. Based on an average trading volume of 825,528 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the shares of the company are short sold.

Daiichi Sankyo Stock Performance

Shares of DSNKY opened at $15.77 on Friday. The company has a market capitalization of $29.38 billion, a PE ratio of 16.78, a price-to-earnings-growth ratio of 2.70 and a beta of -0.16. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64. Daiichi Sankyo has a one year low of $14.98 and a one year high of $27.50. The company’s fifty day moving average price is $16.55 and its 200 day moving average price is $18.59.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings results on Monday, May 11th. The company reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The firm had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, analysts expect that Daiichi Sankyo will post 0.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research report on Tuesday, May 5th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Daiichi Sankyo presently has a consensus rating of “Hold”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody?drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.